Thomas Andrew Crockett - Feb 17, 2023 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CEO, Director
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Feb 17, 2023
Transactions value $
-$51,322
Form type
4
Date filed
2/23/2023, 04:40 PM
Previous filing
May 19, 2023
Next filing
Aug 21, 2023
SEC
View on sec.gov
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +12.7K +11.1% 128K Feb 17, 2023 Direct F1
transaction KALV Common Stock Sale -$51.3K -6.7K -5.25% $7.66 121K Feb 17, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Performance Restricted Stock Unit Options Exercise $0 +6.94K $0.00* 0 Feb 17, 2023 Common Stock 6.94K Direct F1, F3
transaction KALV Restricted Stock Unit Options Exercise $0 -5.81K -7.14% $0.00 75.5K Feb 17, 2023 Common Stock 5.81K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 Shares earned upon the vesting of a percentage of the performance restricted stock units ("PRSUs") granted to the Reporting Person on January 11, 2023. Each PRSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/12th of the total number of shares subject to the PSRU shall vest on each quarterly anniversary of the Vesting Commencement Date of November 17, 2022, upon Performance Metrics achieved, subject to continued service through each vesting date.
F4 1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.